L-Theanine Administration Modulates the Absorption of Dietary Nutrients and Expression of Transporters and Receptors in the Intestinal Mucosa of Rats.

L-theanine has various advantageous functions for human health; whether or not it could mediate the nutrients absorption is unknown yet. The effects of L-theanine on intestinal nutrients absorption were investigated using rats ingesting L-theanine solution (0, 50, 200, and 400 mg/kg body weight) per day for two weeks. The decline of insulin secretion and glucose concentration in the serum was observed by L-theanine. Urea and high-density lipoprotein were also reduced by 50 mg/kg L-theanine. Jejunal and ileac basic amino acids transporters SLC7a1 and SLC7a9, neutral SLC1a5 and SLC16a10, and acidic SLC1a1 expression were upregulated. The expression of intestinal SGLT3 and GLUT5 responsible for carbohydrates uptake and GPR120 and FABP2 associated with fatty acids transport were inhibited. These results indicated that L-theanine could inhibit the glucose uptake by downregulating the related gene expression in the small intestine of rats. Intestinal gene expression of transporters responding to amino acids absorption was stimulated by L-theanine administration.

1. Introduction

L-theanine, as a non-protein-forming amino acid (AA), contributes to the umami taste and unique flavor of green tea. Its content in tea leaves is closely related to the quality and price of green tea [1, 2]. L-theanine is beneficial for remedying various nutritional and metabolic diseases in human, including providing antiobesity effects [3, 4], suppressing the body weight increases and fat accumulation [3, 5], and exerting antidiabetic effects [6, 7]. L-theanine is transported through the intestinal brush border membrane mainly via neutral AA systems B, A, ASC, N, and L, based on findings that L-theanine inhibited the absorption of glutamine and large neutral amino acids (AAs, leucine, and tryptophan) into organs [8-10]. Our knowledge data and previous findings also confirmed that most neutral AAs (threonine, valine, methionine, isoleucine, serine, alanine, tyrosine, and leucine) and certain basic AA (lysine) in the serum of L-theanine-administered rats were decreased [8, 11]. These researches indicated that L-theanine could competitively suppress the absorption of AAs.

However, AAs absorption is dependent on the activities of AA transporters located in the brush border membrane of small intestine. Neutral AA transporters, solute carrier family 1, member 5 (SLC1a5) and family 16, member 10 (SLC16a10), are responsible for threonine, serine, alanine, cysteine, glutamine and phenylalanine, tyrosine, and tryptophan transporting, respectively. Basic AA transporters, solute carrier family 7, member 1 (SLC7a1) and member 9 (SLC7a9), are in charge of transporting arginine, lysine, histidine, alanine, serine, cysteine, threonine, asparagine, and glutamine. Acidic AA transporters solute carrier family 1, member 1 (SLC1a1) and member 2 (SLC1a2) transport glutamate and aspartate. It is reported that L-theanine competitively inhibited the uptake of glutamate substrate through solute carrier family 1, member 3 (SLC1a3) and SLC1a2 expressed in cancer cells [12, 13]. However, the expression pattern of glutamate transporter subtypes in tumor cells is different from normal cells. Therefore, it is necessary to investigate the efficacy of L-theanine on glutamate transporters in normal tissues. Whether or not the expression of different AA transport systems is mediated by L-theanine is unknown yet.

Furthermore, it is reported that the fatty accumulation in mice was suppressed by the administration of green tea powder [4] and theanine was responsible for this suppressive effect [3]. Although serum glucose in rats was not changed, the insulin was reduced by oral theanine [14]. These literatures indicate that metabolism of lipid and insulin is regulated by L-theanine. In the enterocytes of rats, there are many transporters and receptors responses to sugar and fatty acids transport, including sodium dependent glucose transporters (SGLTs), glucose transporters, G-protein-coupled receptors, and fatty acid binding protein 2 (FABP2) [15-21]. Whether these transporters and receptors involved in the regulation of L-theanine administration on absorption of glucose and lipid is unclear. Based on these questions, we measured the nutrient content in the blood and mRNA expression of related transporters and receptors in small intestine of rats after the intragastric administration of L-theanine for two weeks, aiming at figuring out the preliminary L-theanine-induced regulation mechanism in nutrients absorption in rats.

2. Material and Methods

2.1. Experimental Design

This experiment was conducted according to the animal care guidelines of the Animal Care Committee, Institute of Subtropical Agriculture, the Chinese Academy of Sciences, Changsha city, Hunan province, China (number KYNEAAM-2013-0009). Sixty-four Sprague Dawley (SD) rats which are 3 weeks old weighing 74–92.2 g were used as experimental animals. The management of SD rats and L-theanine administration experiment was the same as Li et al. [22]. The animals were individually housed in plastic cages under laboratory conditions (25 ± 3°C, 70 ± 5% relative humidity, good ventilation, and a 12-h light-dark cycle) and had free access to food and pure water. After three days of adaptation, SD rats were randomly divided into four treatment groups. Each group contained eight male rats and eight female rats. During fasting (15:00–17:00 h), rats in the treatments received gastric intubation of four different doses of L-theanine (0, 50, 200, and 400 mg/kg body weight/day), respectively. L-theanine was freshly dissolved in 0.9% NaCl solution in advance before intubation every day. 1 mL of the L-theanine solution was daily administered to each rat for two weeks.

2.2. Blood and Tissue Samples Collection

At the end of the experiment, SD rats were fasted overnight and anesthetized by ether for 4 min, and then blood was collected from the jugular vein into tubes without anticoagulant. The blood samples were centrifuged at 3500 rpm for 15 min at 4°C, and then serum samples were collected and stored at −80°C until assay. The whole jejunum and ileum segments were collected and rinsed with ice-cold saline (0.9% NaCl wt/vol). Then the mucosae were carefully removed, quickly frozen in liquid nitrogen, and stored at −80°C prior to subsequent analyses.

2.3. Analysis of Serum

The glucose, total cholesterol, triglyceride (TG), urea, low-density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) were determined by automatic biochemistry analyzer (Synchron Clinical System CX4 PRO, Beckman Coulter, USA) according to the instructions. Insulin was assayed by the ELISA kit purchased from Huamei Biotechnology Co., Ltd. (Wuhan, Hubei, China). Non-esterified fatty acids (NEFA) were measured by kit produced by Nanjing Jiancheng Bioengineering Institute (Nanjing, Jiangsu, China).

2.4. Real-Time Quantitative PCR

Total RNA was isolated from the mucosa of jejunum and ileum using the Trizol Reagent (Invitrogen, USA), and cDNA was synthesized using the Revert Aid First Strand cDNA synthesis kit (Applied Biosystems, Thermo Fisher Scientific, USA). For relative quantification of gene expression, the ABI Prism 7900 HT Fast Real-Time PCR System (Applied Biosystems, Foster, CA) was used. Primers were designed using the Primer 3 plus program, and sequences are listed in Table 1. The reaction system contained 5 μL SYBR® Premix Ex Taq™ (2x), 0.4 μL PCR forward primer (10 μM), 0.4 μL PCR reverse primer (10 μM), 0.2 μL ROX reference dye (50x), 1.0 μL cDNA, and 3 μL sterilized ddH2O. The thermal profile for all reactions was 30 s at 95°C, then 40 cycles of denaturation at 95°C for 5 s, and annealing at 60°C for 30 s. Each reaction was completed with a melting curve analysis to ensure the specificity of the reaction. All the samples were analyzed in duplicate, and the relative amount of each specific transcript was obtained after normalization against the endogenous control β-actin. The relative amounts of target genes were quantified according to the 2−ΔΔCT method [23].

Table 1

Sequences of primers used for real-time quantitative PCR.

Gene	GenBank accession	Primer	Length (bp)
SLC7a1	NM_013111.3	Forward-CCTTCATCACTGGCTGGAACReverse-GGTTTGCCTATCAGCTCGTC	100
SLC1a5	NM_175758.3	Forward-GGAGAAATGGACTGGGTGTGReverse-CCAGCAAGAAGGCTCTGAAT	107
SLC1a2	NM_001035233.1	Forward-GGCAGTCATCTCCCTGTTGAReverse-AGACATTCATCCCGTCCTTG	101
SLC1a1	NM_013032.3	Forward-GGAGTCTTGGTTCGAGGACAReverse-GTGGCAGAATGACGAGCTTC	106
SLC16a10	NM_138831.1	Forward-TCACTGGTCATTCTGGGACAReverse-CCTAACAGCAAAGGGAGCAA	107
SLC7a9	NM_053929.1	Forward-ACCAAGTCAGGGGGTGAGTAReverse-AGATGATGGCGAAGGATGAG	115
SGLT1	NM_013033	Forward-GCCATCATCCTCTTCGCTATReverse-CGCTCTTCTGTGCTGTTACG	122
SGLT3	NM_001106383	Forward-GATGCTGGTGCTGAAACTGAReverse-CGCTGTTGAAGATGGAGGTC	101
GLUT2	NM_012879	Forward-GATTGCTCCAACCACACTCAReverse-CCTGATTGCCCAGAATGAAG	113
GLUT5	NM_031741	Forward-GGGCTCTTGGTCACACACAReverse-CGTCTTGTCTCTCGGCAACT	108
FATP	NM_053580.2	Forward-GGAAGGTTGCTGTGGTGTTCReverse-ATGGGAGCCAGAAGGGTAGA	120
GPR43	NM_001005877	Forward-AGGCTGTGGTGTTCAGTTCCReverse-GGGATTGCGGAGTAGTAGCA	113
GPR120	NM_001047088.1	Forward-AGACCACCGTTCTGGGACTReverse-GAAGAGGTTGAGCACCAAGC	119
FABP2	NM_013068.1	Forward-GAGGCCAAGCGGATCTTTAReverse-TGCATTATCAGCGAGATGGA	109
β-actin	NM_031144.3	Forward-TGTCACCAACTGGGACGATAReverse-GGGGTGTTGAAGGTCTCAAA	165

2.5. Statistical Analysis

Statistical analyses were conducted by one-way analysis of variance (ANOVA) using the Mixed Proc of SAS (version 8.2, SAS Institute, Cary, NC, USA). The main effect tested was the dose of L-theanine. When indicated by ANOVA, means were separated using least significant differences. Significance was declared at P < 0.05.

3. Results

As shown in Table 2, glucose concentration was decreased by 400 mg/kg L-theanine administration compared to the control group (0 mg/kg L-theanine administration) (P < 0.05). Insulin concentration was linearly decreased by L-theanine administration (P < 0.001). There were no differences (P > 0.05) in the serum cholesterol, TG, NEFA, and LDL concentrations among the L-theanine treatments. Concentrations of urea and HDL were decreased by 50 mg/kg L-theanine treatment compared to the control group (P < 0.05).

Table 2

Effects of L-theanine administration on average daily gain and biochemical parameters in serum of rats.

Item	Treatments (mg/kg BW·d)				P value
	0	50	200	400	Linear	Quadratic
Average daily gain, g/d	5.24 ± 0.17b	6.01 ± 0.17a	6.15 ± 0.17a	5.98 ± 0.17a	0.038	<0.01
Glucose, mM	5.65 ± 0.29a	5.31 ± 0.29ab	5.74 ± 0.29a	4.77 ± 0.30b	NS	NS
Insulin, uIU/mL	43.2 ± 2.18a	41.7 ± 2.18a	26.3 ± 2.26b	19.0 ± 3.08c	<0.001	NS
Cholesterol, mM	2.23 ± 0.09	2.08 ± 0.09	2.13 ± 0.09	2.05 ± 0.09	NS	NS
Triglyceride, mM	1.23 ± 0.07	1.21 ± 0.07	1.02 ± 0.07	1.16 ± 0.07	NS	NS
NEFA, mM	1.27 ± 0.13	1.35 ± 0.10	1.45 ± 0.11	1.31 ± 0.10	NS	NS
Urea, mM	5.42 ± 0.16a	4.85 ± 0.16b	5.70 ± 0.16a	5.38 ± 0.17a	NS	NS
LDL, mM	0.339 ± 0.02	0.341 ± 0.02	0.354 ± 0.02	0.347 ± 0.02	NS	NS
HDL, mM	1.74 ± 0.06a	1.52 ± 0.06b	1.60 ± 0.06ab	1.60 ± 0.06ab	NS	NS

BW: body weight, NEFA: non-esterified fatty acids, LDL: low-density lipoprotein, HDL: high-density lipoprotein, and NS: not significant. a–c Means within a row not bearing a common superscript letter differ (P < 0.05). Data were reported as mean ± SE. Data of average daily gain were cited by Tong et al. (2016).

Transcript levels of intestinal AA transporters in the intestine of rats are shown in Table 3. Expression of acidic AA transporter SLC1a1 was upregulated in the jejunum and ileum (Quadratic, P < 0.001), while jejunal SLC1a2 transcript was linearly decreased (P < 0.001) with the increasing doses of L-theanine but increased by L-theanine treatments in the ileum (Quadratic, P < 0.05). Expression of neutral AA transporter SLC1a5 was increased by doses of L-theanine (jejunum, Linear, P < 0.001; ileum, Linear and Quadratic, P < 0.001); therein the maximal values both occurred in the 400 mg/kg L-theanine treatment. Another neutral AA transporter SLC16a10 expression in the jejunum and ileum was upregulated by doses of L-theanine (Quadratic, P < 0.001). Basic AA transporters SLC7a1 (jejunum, Linear, P < 0.01; ileum, Linear and Quadratic, P < 0.001) and SLC7a9 expression (jejunum, Quadratic, P < 0.001; ileum, Linear and Quadratic, P < 0.001) was increased with the increasing doses of L-theanine.

Table 3

Effects of L-theanine administration on the transcript levels of AA transporters in rat intestine.

Item	Treatments (mg/kg BW·d)				P value
	0	50	200	400	Linear	Quadratic
Jejunum
SLC1a1	1.00b	1.71 ± 0.43b	7.70 ± 0.50a	1.12 ± 0.55b	NS	<0.001
SLC1a2	1.00a	0.34 ± 0.06c	0.63 ± 0.07b	0.23 ± 0.07c	<0.001	NS
SLC1a5	1.00b	1.77 ± 0.43b	1.61 ± 0.38b	3.49 ± 0.41a	<0.001	NS
SLC16a10	1.00c	7.17 ± 0.84a	5.25 ± 0.79ab	3.83 ± 0.68b	NS	<0.001
SLC7a1	1.00c	8.40 ± 0.70a	3.93 ± 0.90b	8.88 ± 1.28a	0.0017	NS
SLC7a9	1.00c	6.40 ± 0.60b	10.9 ± 0.66a	1.70 ± 0.60c	NS	<0.001
Ileum
SLC1a1	1.00b	4.89 ± 0.35a	5.11 ± 0.39a	1.25 ± 0.39b	NS	<0.001
SLC1a2	1.00	1.47 ± 0.29	1.86 ± 0.24	1.02 ± 0.44	NS	0.01
SLC1a5	1.00b	1.45 ± 0.35b	0.94 ± 0.37b	4.45 ± 0.45a	<0.001	<0.001
SLC16a10	1.00c	8.27 ± 0.27b	13.1 ± 0.63a	1.52 ± 0.77c	NS	<0.001
SLC7a1	1.00b	1.71 ± 0.34b	1.18 ± 0.36b	4.62 ± 0.45a	<0.001	<0.001
SLC7a9	1.00b	1.93 ± 0.42b	7.21 ± 0.52a	2.09 ± 0.42b	<0.001	<0.001

BW: body weight, SLC1a1: solute carrier family 1, member 1, SLC1a2: solute carrier family 1, member 2, SLC1a5: solute carrier family 1, member 5, SLC16a10: solute carrier family 16, member 10, SLC7a1: solute carrier family 7, member 1, SLC7a9: solute carrier family 7, member 9, and NS: not significant.  a–cMeans within a row not bearing a common superscript letter differ (P < 0.05). Data were reported as mean ± SE.

Gene expressions of glucose transporters and receptors in the intestine of rats are shown in Table 4. Transcript level of SGLT1 in the jejunum was stimulated (P < 0.05) by 400 mg/kg L-theanine compared to the 200 mg/kg L-theanine treatment, while in the ileum it was downregulated (Quadratic, P < 0.001); therein a minimum value appeared at the 200 mg/kg L-theanine group. SGLT3 expression in the jejunum and ileum was decreased by L-theanine treatment (jejunum, Linear, P < 0.001; ileum, Linear and Quadratic, P < 0.001). Comparing with the 50 mg/kg L-theanine treatment, jejunal GLUT2 expression was suppressed (P < 0.05) by 200 mg/kg L-theanine. Ileac GLUT2 expression was upregulated (P < 0.01) by 50 mg/kg L-theanine and then inhibited (P < 0.05) by high doses of L-theanine treatments compared to 50 mg/kg L-theanine. Jejunal GLUT5 expression was inhibited (P < 0.05) by high doses of L-theanine treatment compared to the control group, while its expression in the ileum was linearly decreased (P < 0.01) by increasing doses of L-theanine.

Table 4

Effects of L-theanine administration on the transcript levels of glucose transporters and receptors in rat intestine.

Item	Treatments (mg/kg BW·d)				P value
	0	50	200	400	Linear	Quadratic
Jejunum
SGLT1	1.00ab	1.14 ± 0.20ab	0.80 ± 0.21b	1.65 ± 0.21a	NS	NS
SGLT3	1.00ab	1.06 ± 0.15a	0.53 ± 0.16b	0.03 ± 0.15c	<0.001	NS
GLUT2	1.00ab	1.44 ± 0.2a	0.77 ± 0.20b	1.12 ± 0.17ab	NS	NS
GLUT5	1.00a	0.16 ± 0.08c	0.72 ± 0.10b	0.68 ± 0.10b	NS	NS
Ileum
SGLT1	1.00a	0.60 ± 0.12b	0.17 ± 0.11c	1.10 ± 0.09a	NS	<0.001
SGLT3	1.00a	0.61 ± 0.07b	0.26 ± 0.06c	0.01 ± 0.005d	<0.001	<0.001
GLUT2	1.00c	3.07 ± 0.30a	1.31 ± 0.33bc	1.99 ± 0.30b	NS	NS
GLUT5	1.00a	0.58 ± 0.10b	0.53 ± 0.11b	0.46 ± 0.11b	0.003	NS

BW: body weight, SGLT1: sodium dependent glucose transporter 1, SGLT3: sodium dependent glucose transporter 3, GLUT2: glucose transporter protein, member 2, GLUT5: glucose transporter protein, member 5, and NS: not significant.  a–dMeans within a row not bearing a common superscript letter differ (P < 0.05). Data were reported as mean ± SE.

The mRNA abundance of the fatty acid transporters and receptors in the intestine of rats is shown in Table 5. Jejunal FATP expression was decreased by L-theanine treatments (Quadratic, P < 0.01), while its expression levels in the treatments of 50 and 400 mg/kg L-theanine were lower (P < 0.01) than that of control group and 200 mg/kg L-theanine treatment. Ileac FATP expression was not affected by L-theanine treatments (P > 0.05). Jejunal GPR43 expression was unchanged by L-theanine treatments (P > 0.05). However, its expression in the ileum of 50 mg/kg L-theanine treatment was decreased (P < 0.05) compared with control group and 200 mg/kg L-theanine treatment. GPR120 (jejunum, Linear and Quadratic, P < 0.001; ileum, Linear, P < 0.001) and FABP2 (jejunum, Linear, P < 0.001; ileum, Linear and Quadratic, P < 0.001) expression levels were both suppressed by L-theanine treatments.

Table 5

Effects of L-theanine administration on the transcript levels of fatty acid transporters and receptors in rat intestine.

Item	Treatments (mg/kg BW·d)				P value
	0	50	200	400	Linear	Quadratic
Jejunum
FATP	1.00ab	0.27 ± 0.03b	1.86 ± 0.07a	0.40 ± 0.03b	NS	0.007
GPR43	1.00	0.79 ± 0.49	1.23 ± 0.57	0.86 ± 0.61	NS	NS
GPR120	1.00a	0.25 ± 0.03b	0.18 ± 0.03b	0.06 ± 0.03c	<0.001	<0.001
FABP2	1.00a	0.52 ± 0.08b	0.51 ± 0.08b	0.09 ± 0.08c	<0.001	NS
Ileum
FATP	1.00	1.52 ± 0.19	1.00 ± 0.19	1.76 ± 0.39	NS	NS
GPR43	1.00a	0.56 ± 0.13b	0.72 ± 0.14ab	1.02 ± 0.14a	NS	0.07
GPR120	1.00a	0.36 ± 0.11bc	0.64 ± 0.11b	0.21 ± 0.12c	<0.001	NS
FABP2	1.00a	0.38 ± 0.05b	0.16 ± 0.05c	0.08 ± 0.05c	<0.001	<0.001

BW: body weight, FATP: fatty acid transport protein, GPR43: G-protein-coupled receptor 43, GPR120: G-protein-coupled receptor 120, FABP2: fatty acid binding protein 2, and NS: not significant. a–cMeans within a row not bearing a common superscript letter differ (P < 0.05). Data were reported as mean ± SE.

4. Discussion

To the best of our knowledge, this experiment is a new attempt to investigate the link between serum nutrients and the expression of nutrient-associated transporters and receptors in the small intestine of L-theanine-administered rats. In this study, the declines of glucose, insulin, and urea in the serum were observed by L-theanine administration, indicating that L-theanine could inhibit the absorption of glucose, nitrogen, and secretion of insulin. Our results are partly in line with the data of Yamada et al. (2008) which observed reduced insulin level with unchanged glucose concentration in the serum of rats administrated by 4 g/kg oral L-theanine. These results are inconsistent with the findings of Zheng et al. (2004) which discovered that TG and NEFA levels in the serum of mice were decreased by 0.03% L-theanine administration. This discrepancy appears to be due to the dosage of L-theanine ingested, method of administration, and experimental period.

The upregulating effects of L-theanine are reflected in the AA transporters expression at the mRNA level in small intestine in this study, except SLC1a2. This finding can partly explain the increased AAs concentrations in rat serum after L-theanine ingestion [11], including acidic acid (aspartic acid and glutamic acid), neutral acid (glutamine), and basic acid (histidine) (see Supplemental Table 1 in [11]; see Supplementary Material available online at https://doi.org/10.1155/2017/9747256), indicating that L-theanine promotes the AAs absorption in rat small intestine. The opposing effect of L-theanine on jejunal SLC1a2 expression was observed, reflecting that asparagine absorption in the jejunum might be blocked by L-theanine. Although direct evidences about the regulatory mechanism of AA transporters transcription by L-theanine are lacking, previous literatures showed that activating transcription factor 4 (ATF4) could transcriptionally upregulate SLC7a1 [24] and regulatory factor X proteins (RFXs) induced mRNA of SLC1a1 [25]. After MatInspector online analysis [26], we find that there are ATF4 binding sites in the promoter regions of SLC7a1 (between nucleotides +10 and +18) and SLC7a9 (between nucleotides −155 and −146) genes and RXFs located in SLC1a1 (between nucleotides −239 and −86) promoter sequence. Additionally, elements for E-box binding factors (EBOX) and cAMP-responsive element binding proteins (CREB) binding are identified in the promoter sequences of SLC1a5, SLC7a1, and SLC7a9 genes. Therefore, we speculated that L-theanine, as an amino acid, changed SLC1a1, SLC1a5, SLC7a1, and SLC7a9 mRNA transcription via acting with ATF4, RXF, EBOX, and CREB proteins.

Glucose transporting from the intestinal lumen to the blood mainly depends on Na+-glucose cotransporter SGLT1, which absorbs glucose and galactose and the passive glucose transporter GLUT2, which acts as a glucose sensor [27-30]. SGLT3 is also a glucose sensor in cholinergic neurons neighboring enterocytes and induces membrane currents upon Na+-glucose binding [27]. GLUT5 is primarily in charge of fructose absorption into the cytosol. Although decreases in SGLT1 and GLUT2 mRNA abundance in the intestine of rats receiving 200 mg/kg L-theanine, in which glucose absorption was declined, were not observed in this study, we found that intestinal SGLT3 and ileac GLUT5 transcripts in L-theanine-ingested rats were decreased in a dose-dependent manner. These results indicated that rats intestinal GLUT2 was less impressible than GLUT5 to L-theanine administration at the transcriptional level, and SGLT3 and GLUT5 genes rather than SGLT1 and GLUT2 play a role in intestinal glucose absorption of L-theanine-ingested rats. It is reported that period circadian clock 1 (PER1) exerted an indirect suppressive effect on rat SGLT1 promoter [31] and hepatic nuclear factors (HNF) regulated SGLT1 and GLUT2 promoter activities [32, 33]. By analyzing [26], we also identified HNF-element located in SGLT3 and peroxisome proliferator-activated receptor (PPARG) element encompassed in GLUT5 promoter regions. Therefore, we predicted that L-theanine may target transcription factors (PER1, HNF, and PPARG) and further inhibit the expression of glucose transporters mRNA.

It is reported that GPR43 binds short-chain fatty acids, whereas GPR120 responds to medium and long chain fatty acids [34, 35]. FABP2 also displays high-affinity binding for long chain fatty acids and is believed to be involved with uptake and trafficking of lipids in the intestine [21]. In the present study, GPR120 and FABP2 transcripts in jejunum and ileum were decreased by L-theanine. Jejunal FATP mRNA was also suppressed by 50 mg/kg and 400 mg/kg L-theanine. However, triglyceride and cholesterol contents in the serum of L-theanine-treated rats were not affected (Table 2). These results state that the intestinal uptake of dietary fatty acids might have been inhibited by L-theanine. Further research is needed to explore the regulatory mechanism of L-theanine on intestinal uptake of dietary lipids.

In summary, L-theanine administration had decreased serum glucose probably by inhibiting intestinal SGLT3 and GLUT5 mRNA expression in rats. Dietary fatty acids uptake might be suppressed by downregulating GPR120 and FABP2 transcripts in the intestine of rats. Meanwhile, intestinal transporters responding to AAs absorption were upregulated by L-theanine administration. Our data provide theoretical basis for further investigation of L-theanine and nutrients interaction.

Effects of L-Theanine administration on serum amino acids profiles in rat.